Senate Committee Discusses Abortion Pill Regulations
During a hearing on Wednesday, a Senate committee focused on health policy discussed the regulation of the abortion pill mifepristone. Some Republican members urged the government to tighten access to this medication.
Sen. Bill Cassidy from Louisiana, who chairs the Senate Committee on Health, Labor, Education, and Pensions, criticized a policy approved under former President Joe Biden that has allowed mifepristone to be sent by mail. “At a bare minimum, we should immediately restore the previous in-person safeguards for accessing the pill,” he stated in his opening remarks.
Starting in 2021, the FDA, under Biden’s administration, began to lift the long-standing requirement for in-person dispensing of abortion pills, permitting women to receive mifepristone through the mail. Guttmacher reported that this pill was used in 63% of abortions in the U.S. in 2023, a rise from 53% in 2020 and 39% in 2017.
Cassidy and fellow Republicans argued that allowing mail-order mifepristone is careless due to potential side effects associated with the drug. He also called on Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary to complete a safety review of mifepristone, a promise made during their confirmation hearings.
A spokesperson from HHS mentioned that the agency continues to review adverse events related to mifepristone to ensure adequate protection for women. “The FDA’s scientific review process is meticulous and aims to ensure that decisions are based on the best available science,” the statement added.
During the hearing, two witnesses invited by the Republicans spoke out. Louisiana Attorney General Liz Murrill shared instances of illegal mail orders of abortion pills in her state. Meanwhile, Dr. Monique Chireau Wubbenhorst, an obstetrician-gynecologist from North Carolina, described the waiver of in-person requirements as medically irresponsible.
Sen. Bernie Sanders, the committee’s ranking Democrat, largely dismissed these positions. “This hearing isn’t about drug safety. It’s part of an ongoing attempt by some in the Republican Party to deny women the right to make decisions about their own bodies,” Sanders remarked.
Dr. Nisha Verma, the minority-invited witness who performs abortions, defended the safety of mifepristone. “There are over 100 high-quality peer-reviewed studies confirming its safety and efficacy. Perhaps it’s worth noting that this discussion reflects unease some may have about abortion itself, rather than the science,” Verma observed.
Verma also touched on various political issues, including Medicaid funding and immigration policies, emphasizing how these affect her patients’ safety and care access.
Sen. Jim Banks from Indiana joined Cassidy in pushing for stronger regulations on mifepristone. “I’m frustrated that under Dr. Makary’s leadership, the FDA hasn’t acted more swiftly to reinstate in-person dispensing requirements for mifepristone,” Banks expressed.
REMS, or risk evaluation and mitigation strategies, is a monitor system for high-risk medications. Mifepristone was placed under REMS when it first received approval in 2000.
Throughout the hearing, Democrats defended the safety of mifepristone. Sen. Patty Murray from Washington asserted, “Medication abortion is safe and effective, a fact well established over time. The FDA had the data to confirm this when they first approved it 25 years ago, and its safety was reaffirmed with the recent approval of a generic version.”
Banks countered this perspective by highlighting the drug’s black box warning, which advises users to maintain contact with healthcare providers regarding potential severe side effects. He questioned Dr. Wubbenhorst about whether online telehealth services adequately inform patients of these risks.
“They do not,” she replied. “I’ve checked these services, and they fail to mention important warnings about serious side effects.”
